直接抗病毒药物时代HBV/HCV重叠感染的治疗

王程; 廖家杰

doi:10.3969/j.issn.1001-5256.2017.06.001

直接抗病毒药物时代HBV/HCV重叠感染的治疗

DOI: 10.3969/j.issn.1001-5256.2017.06.001

王程,
廖家杰

1. 南方医科大学附属南方医院感染内科

详细信息

中图分类号: R512.6
计量
- 文章访问数: 2234
- HTML全文浏览量: 33
- PDF下载量: 575
- 被引次数: 0
出版历程
- 收稿日期: 2017-05-17
- 出版日期: 2017-06-20

Treatment of HBV/HCV co-infected patients in DAA era

Department of infectious diseases, Nanfang Hospital, Southern Medical University

摘要

摘要: 亚太地区,尤其是我国,为HBV感染高发地区,自2011年口服直接抗病毒药物(DAA)问世以来,抗HCV的治疗逐渐从IFN为基础的方案转向全口服药物方案。进入DAA抗HCV治疗的时代后,陆续观察到HBV再激活的发生,相比IFN治疗时期,HBV再激活发生得更早、更严重,甚至有HBV再激活相关的死亡病例及肝移植病例的报道。因此,全世界各大肝病学会都高度重视DAA时代HBV再激活的发生,此类药物的说明书也新增了黑框药物用药安全警示,警示患者在接受DAA抗HCV治疗前,必须筛查HBV感染标志物,并在开始DAA抗HCV治疗前、治疗中及治疗后,密切检测HBV再激活的发生,并且在必要时,及时开始启动抗HBV治疗。
- 肝炎病毒,乙型 /
- 肝炎病毒属 /
- 重叠感染 /
- 抗病毒药 /
- 治疗 /
- 述评
Abstract: Asian-pacific area, especially China, is Hepatitis B high epidemic area. Since 2011, the first generation of oral direct anti-HCV agents (DAAs) came to clinical use, the treatment of chronic hepatitis C has switched from interferon-based regimen era to DAA era.There is an increased awareness of hepatitis B (HBV) reactivation in chronic hepatitis C (CHC) patients coinfected with HBV treated with pan-oral direct-acting antivirals (DAAs) . Compared with interferon-based regimen, HBV reactivation occurred earlier and more severe among patients received DAA regimen, and even fetal cases or case end up with liver transplantation was reported. Thus, association of liver diseases called to alert the occurrence of HBV reactivation among CHC patients who received DAAs regimen. It is hence important to have HBV serology screened in all CHC patients before initiation of pan-oral DAAs therapy and the usefulness of preemptive administration of effective anti-HBV nucleos (t) ide analogues in coinfected patients need to be further studied.
- hepatitis B virus /
- hepacivirus /
- superinfection /
- antiviral agents /
- therapy /
- editorial

HTML全文

参考文献(37)

[1]European Association for Study of Liver.EASL recommendations on treatment of hepatitis C 2015[J].J Hepatol, 2015, 63 (1) :199-236.

[2]WEI L, LOK AS.Impact of new hepatitis C treatments in different regions of the world[J].Gastroenterology, 2014, 146 (5) :1145-1150.

[3]YONGHAO G, JIN X, JUN L, et al.An epidemiological serosurvey of hepatitis B virus shows evidence of declining prevalence due to hepatitis B vaccination in central China[J].Int J Infect Dis, 2015, 40:75-80.

[4]SAGNELLI E, COPPOLA N, PISATURO M, et al.HBV superinfection in HCV chronic carriers:a disease that is frequently severe but associated with the eradication of HCV[J].Hepatology, 2009, 49 (4) :1090-1097.

[5]KONSTANTINOU D, DEUTSCH M.The spectrum of HBV/HCV coinfection:epidemiology, clinical characteristics, viralinteractions and management[J].Ann Gastroenterol, 2015, 28 (2) :221-228.

[6]YU G, CHI X, WU R, et al.Replication inhibition of hepatitis B virus and hepatitis C virus in co-infected patients in Chinese population[J].PLo S One, 2015, 10 (9) :e0139015.

[7]WANG C, JI D, CHEN J, et al.Hepatitis due to reactivation of hepatitis B virus in endemic areas among patients with hepatitis C treated with direct-acting antiviral agents[J].Clin Gastroenterol Hepatol, 2017, 15 (1) :132-136.

[8]WU JC, CHEN CL, HOU MC, et al.Multiple viral infection as the most common cause of fulminant and subfulminant viral hepatitis in an area endemic for hepatitis B:application and limitations of the polymerase chain reaction[J].Hepatology, 1994, 19 (4) :836-840.

[9]PONTISSO P, RUVOLETTO MG, FATTOVICH G, et al.Clinical and virological profiles in patients with multiple hepatitis virus infections[J].Gastroenterology, 1993, 105 (5) :1529-1533.

[10]CHU CM, SHEEN IS, LIAW YF.The role of hepatitis C virus in fulminant viral hepatitis in an area with endemic hepatitis A and B[J].Gastroenterology, 1994, 107 (1) :189-195.

[11]RAIMONDO G, ALLAIN JP, BRUNETTO MR, et al.Statements from the Taormina expert meeting on occult hepatitis B virus infection[J].J Hepatol, 2008, 49 (4) :652-657.

[12]CACCIOLA I, POLLICINO T, SQUADRITO G, et al.Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease[J].N Engl J Med, 1999, 341 (1) :22-26.

[13]CHO LY, YANG JJ, KO KP, et al.Coinfection of hepatitis B and C viruses and risk of hepatocellular carcinoma:systematic review and meta-analysis[J].Int J Cancer, 2011, 128 (1) :176-184.

[14]OH JK, SHIN HR, LIM MK, et al.Multiplicative synergistic risk of hepatocellular carcinoma development among hepatitis B and C co-infected subjects in HBV endemic area:a community-based cohort study[J].BMC Cancer, 2012, 12:452.

[15]FONG TL, Di BISCEGLIE AM, WAGGONER JG, et al.The significance of antibody to hepatitis C virus in patients with chronic hepatitis B[J].Hepatology, 1991, 14 (1) :64-67.

[16]DONATO F, BOFFETTA P, PUOTI M.A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma[J].Int J Cancer, 1998, 75 (3) :347-354.

[17]CHIARAMONTE M, STROFFOLINI T, VIAN A, et al.Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis[J].Cancer, 1999, 85 (10) :2132-2137.

[18]di BISCEGLIE AM, LOK AS, MARTIN P, et al.Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs:just the tip of the iceberg?[J].Hepatology, 2015, 61 (2) :703-711.

[19]HWANG JP, LOK AS.Management of patients with hepatitis B who require immunosuppressive therapy[J].Nat Rev Gastroenterol Hepatol, 2014, 11 (4) :209-219.

[20]Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B:a 2015 update[J].J Clin Hepatol, 2015, 31 (12) :1941-1960. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.慢性乙型肝炎防治指南 (2015年更新版) [J].临床肝胆病杂志, 2015, 31 (12) :1941-1960.

[21]CHEN G, WANG C, CHEN J, et al.Hepatitis B reactivation in hepatitis B and C coinfected patients treated with antiviral agents:a systematic review and meta-analysis[J].Hepatology, 2017.[Epub ahead of print]

[22]COLLINS JM, RAPHAEL KL, TERRY C, et al.Hepatitis B virus reactivation during successful treatment of hepatitis C virus with sofosbuvir and simeprevir[J].Clin Infect Dis, 2015, 61 (8) :1304-1306.

[23]ENDE AR, KIM NH, YEH MM, et al.Fulminant hepatitis B reactivation leading to liver transplantation in a patient with chronic hepatitis C treated with simeprevir and sofosbuvir:a case report[J].J Med Case Rep, 2015, 9:164.

[24]TAKAYAMA H, SATO T, IKEDA F, et al.Reactivation of hepatitis B virus during interferon-free therapy with daclatasvir and asunaprevir in patient with hepatitis B virus/hepatitis C virus co-infection[J].Hepatol Res, 2016, 46 (5) :489-491.

[25]HAYASHI K, ISHIGAMI M, ISHIZU Y, et al.A case of acute hepatitis B in a chronic hepatitis C patient after daclatasvir and asunaprevir combination therapy:hepatitis B virus reactivation or acute self-limited hepatitis?[J].Clin J Gastroenterol, 2016, 9 (4) :252-256.

[26]de MONTE A, COURJON J, ANTY R, et al.Direct-acting antiviral treatment in adults infected with hepatitis C virus:reactivation of hepatitis B virus coinfection as a further challenge[J].J Clin Virol, 2016, 78:27-30.

[27]PILLAI AA, WEDD J, NORVELL JP, et al.Simeprevir and sofosbuvir (SMV-SOF) for 12 weeks for the treatment of chronic hepatitis C genotype 1 infection:a real world (transplant) hepatology practice experience[J].Am J Gastroenterol, 2016, 111 (2) :250-260.

[28]GANE EJ, HYLAND RH, AN D, et al.Ledipasvir and sofosbuvir for HCV-infection in patients coinfected with HBV[J].Antivir Ther, 2016, 21 (7) :605-609.

[29]U.S.Food and Drug Adminstration.FDA Drug Safety Communication:FDA warns about the risk of hepatitis B reactivating in some patients treated with direct-acting antivirals for hepatitis C[EB/OL].[2016-10-4].https://www.fda.gov/Drugs/Drug Safety/ucm 522932.htm.

[30]YAN LB, RAO HY, MA YJ, et al.Hepatitis B virus infection in Chinese patients with hepatitis C virus infection:prevalence, clinical characteristics, viral interactions and host genotypes:a nationwide cross-sectional study[J].BMJ Open, 2016, 6 (10) :e012016.

[31]BERSOFF-MATCHA SJ, CAO K, JASON M, et al.Hepatitis B Virus reactivation associated with direct-acting antiviral therapy for chronic hepatitis C virus:a review of cases reported to the U.S.food and drug administration adverse event reporting system[J].Ann Intern Med, 2017.[Epub ahead of print]

[32]LAU GK, YIU HH, FONG DY, et al.Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy[J].Gastroenterology, 2003, 125 (6) :1742-1749.

[33]European Association for the Study of the Liver.EASL recommendations on treatment of hepatitis C 2016[J].J Hepatol, 2017, 66 (1) :153-194.

[34]European Association for the Study of the Liver.EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection[J].J Hepatol, 2017.[Epub ahead of print]

[35]OMATA M, KANDA T, WEI L, et al.APASL consensus statements and recommendation on treatment of hepatitis C[J].Hepatol Int, 2016, 10 (5) :702-726.

[36]SARIN SK, KUMAR M, LAU GK, et al.Asian-Pacific clinical practice guidelines on the management of hepatitis B:a 2015 update[J].Hepatol Int, 2016, 10 (1) :1-98.

[37]AASLD IDSA HCV Guidance panel.Recommendations for testing, managing, and treating hepatitis C[J/OL].http://www.hcvguidelines.org/full-report/monitoring-patients-who-are-startinghepatitis-c-treatment-are-treatment-or-have.

施引文献

资源附件(0)

访问统计